| Literature DB >> 24304881 |
Yuya Hashimura1, Kandai Nozu1, Hiroshi Kaito1, Koichi Nakanishi2, Xue Jun Fu1, Hiromi Ohtsubo1, Fusako Hashimoto1, Masafumi Oka1, Takeshi Ninchoji1, Shingo Ishimori1, Naoya Morisada1, Natsuki Matsunoshita1, Naohiro Kamiyoshi1, Norishige Yoshikawa2, Kazumoto Iijima1.
Abstract
X-linked Alport syndrome is caused by mutations in the COL4A5 gene encoding the type IV collagen α5 chain (α5(IV)). Complete absence of α5(IV) in the renal basal membrane is considered a pathological characteristic in male patients; however, positive α5(IV) staining has been found in over 20% of patients. We retrospectively studied 52 genetically diagnosed male X-linked Alport syndrome patients to evaluate differences in clinical characteristics and renal outcomes between 15 α5(IV)-positive and 37 α5(IV)-negative patients. Thirteen patients in the α5(IV)-positive group had non-truncating mutations consisting of nine missense mutations, three in-frame deletions, and one splice-site mutation resulting in small in-frame deletions of transcripts. The remaining two showed somatic mutations with mosaicism. Missense mutations in the α5(IV)-positive group were more likely to be located before exon 25 compared with missense mutations in the α5(IV)-negative group. Furthermore, urinary protein levels were significantly lower and the age at onset of end-stage renal disease was significantly higher in the positive group than in the negative group. These results help to clarify the milder clinical manifestations and molecular characteristics of male X-linked Alport syndrome patients expressing the α5(IV) chain.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24304881 DOI: 10.1038/ki.2013.479
Source DB: PubMed Journal: Kidney Int ISSN: 0085-2538 Impact factor: 10.612